Top-5 Companies Profiting from the Longevity Industry

The longevity sector includes companies operating in several key areas:

• preventive medicine services aimed at early detection and prevention of diseases
• biopharmaceutical and biotechnology development of targeted, gene, cell, and immunotherapies
• products with geroprotective properties, including dietary supplements

Today, the largest share of the longevity-related market belongs to major international biopharmaceutical and biotechnology corporations, since radical life-extension technologies are still mostly at early clinical or preclinical stages.

Top-5 companies by revenue in the longevity segment (2024)

Company overview

1. Roche Holding

• A global pharmaceutical and diagnostics company founded in 1896.
• A leader in biotechnology-based medicines for oncology, autoimmune diseases, ophthalmology, and central nervous system disorders.
• Develops in-vitro diagnostic tests and diabetes self-monitoring solutions.

2. Bristol?Myers Squibb

• Founded in 1887 in the United States and actively operating in oncology, hematology, and immunology.
• Developing CAR-T cell therapy, with two approved products already on the market.
• Operates in more than 30 countries, with most revenue coming from the US and Europe.

3. Merck & Co.

• An international biopharmaceutical company producing medicines and vaccines to treat cancer, infectious diseases, and cardiovascular conditions.
• Operates in more than 70 countries worldwide.

4. Novartis

• A Swiss company formed in 1996 through the merger of Ciba-Geigy and Sandoz.
• Its portfolio includes more than 50 innovative medicines, including an approved gene therapy.
• Focuses on targeted and personalized therapies based on biomarkers.

5. Gilead Sciences

• A biopharmaceutical company focused on viral infections, oncology, and cardiovascular diseases.
• Offers two approved CAR-T cell therapy drugs.
• Operates in more than 30 countries worldwide.

Prices of leading companies’ products and services

The longevity-related segment is characterized by high treatment costs, especially for advanced therapies.

Note: Prices vary depending on region and treatment protocols; some therapies are available only in hospital settings.

Conclusion

Although the portfolios of these companies do not yet include therapies aimed specifically at radical life extension, they significantly contribute to increasing both lifespan and healthspan by providing treatments for life-threatening diseases and advancing cutting-edge technologies such as gene therapy, cell therapy, and immunotherapy.

These companies also invest heavily in research and development, participate in global health initiatives, and support programs aligned with the goals of the United Nations and the World Health Organization. As a result, they remain among the key global leaders shaping the longevity industry.